Company Name
Zhejiang Boxiao Bio-Pharmaceutical Co., Ltd.
Year of Establishment
2020
Company Introduction
In August 2020, Zhejiang Boxiao Biopharmaceutical Co., Ltd.(BXBP), with the capital of RMB 242 million, was established in Hangzhou, China.
It was founded by Mr Bai Hua and a group of seasoned pharmaceutical specialists with decades of pharma background and rich practical experiences.
BXBP is an innovative biopharmaceutical company with a high degree of integration of Research, Production and Sales.
Based on the strategic goal of the integration of "raw materials (API, intermediates) + formulation (improved new and generic drugs) + innovative" from Chinese domestic market and extend to the global market, it provides diversified services for multiple subdivided therapeutic fields in the pharmaceutical industry, and provides innovative drugs and professional solutions for the public solutions.
Our goal is to be one of the most valuable and trustworthy biopharmaceutical company in China.
Main Competitive Advantages
Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service,
Other Competitive Advantages
Co-founded by a group of drug workers with decades of medical background and experience.
Microbial platform, Enzyme engineering platform, Green chemical Technological platform,New Drug Delivery Technology Platform, Multi-production line of Drugs and QC Platform was established.
Patents and Copyright
Looking forward for Long term coopeartion
Milestone
August,2020 Zhejiang Boxiao Bio-Pharmaceutical Co., Ltd. was established.
December,2020 The constuction of Boxiao Bio-pharma was started after sign an admission contract.
May,2021 The construction of united lab with cooperated party.
August,2021 Three technology platforms for APIs was operated.
December,2021 Drug delivery platform was operated, Deyang Bio-Pharmaceutical was established.
September,2022 Intelligent drug preparation production line was operated.
September,2022 Provincial postdoctoral station was established, Drug innovation centre with cooperated university.
April,2023 Drug manufacturing license was awarded.
Feb,2024, ISO9001 was awarded.